In order to bring you the best possible user experience, this site uses Javascript. If you are seeing this message, it is likely that the Javascript option in your browser is disabled. For optimal viewing of this site, please ensure that Javascript is enabled for your browser.

The free consultation period for this content is over.

It is now only available year-round to ESC Professional Members, Fellows of the ESC, and Young combined Members

Comparing the prognostic value of ultra-sensitive cardiac troponin I versus high-sensitivity cardiac troponin T and I among patients with suspected myocardial infarction

Session Poster Session 7

Speaker Raphael Twerenbold

Event : ESC Congress 2018

  • Topic : coronary artery disease, acute coronary syndromes, acute cardiac care
  • Sub-topic : Acute Coronary Syndromes – Epidemiology, Prognosis, Outcome
  • Session type : Poster Session

Authors : R Twerenbold (Basel,CH), M Rubini Gimenez (Basel,CH), J Boeddinghaus (Basel,CH), T Nestelberger (Basel,CH), C Puelacher (Basel,CH), P Badertscher (Basel,CH), J Du Fay De Lavallaz (Basel,CH), D Wussler (Basel,CH), N Kozhuharov (Basel,CH), O Miro (Barcelona,ES), FJ Martin-Sanchez (Madrid,ES), B Morawiec (Katowice,PL), D Keller (Zurich,CH), T Reichlin (Basel,CH), C Mueller (Basel,CH)

R. Twerenbold1 , M. Rubini Gimenez1 , J. Boeddinghaus1 , T. Nestelberger1 , C. Puelacher1 , P. Badertscher1 , J. Du Fay De Lavallaz1 , D. Wussler1 , N. Kozhuharov1 , O. Miro2 , F.J. Martin-Sanchez3 , B. Morawiec4 , D. Keller5 , T. Reichlin1 , C. Mueller1 , 1University Hospital Basel - Basel - Switzerland , 2Hospital Clinic de Barcelona - Barcelona - Spain , 3Hospital Clinic San Carlos - Madrid - Spain , 4Medical University of Silesia, Cardiology Department - Katowice - Poland , 5University Hospital Zurich - Zurich - Switzerland ,

European Heart Journal ( 2018 ) 39 ( Supplement ), 1366

Background: Cardiac Troponin (cTn) is a powerful prognostic predictor of death and reinfarction in patients with suspected myocardial infarction (MI). It is unknown, whether the prognostic performance of a novel ultra-sensitive cardiac troponin I assay (us-cTnI-Clarity) with about 10-times higher analytical sensitivity is superior to the two best-in-class high-sensitivity cardiac troponin (hs-cTn) assays.

Purpose: We aimed to assess and directly compare the prognostic performance of us-cTnI and hs-cTnT/I.

Methods: In a prospective international multicentre diagnostic study enrolling patients presenting with suspected MI to the emergency department (ED), us-cTnI-Clarity, hs-cTnI-Architect and hs-cTnT-Elecsys was determined at baseline. Patients presenting with STEMI were excluded. Co-primary prognostic endpoints were all-cause mortality and future MI (excluding the index events) within two years. Time-dependent ROC curves were constructed to directly compare the predictive performance of the three investigated cTn-assays within two years.

Results: Among 1974 patients presenting with suspected MI to the ED, median follow-up time was 778 days (IQR, 734–913). Mortality at 30 days and two years was 0.8% (16/1974) and 6.5% (129/1974), respectively. Prevalence of MI at index admission was 17.4% (343/1974). Incidence of MI following the index admission was 1.3% (25/1974) and 4.9% (96/1974), respectively.

For the prediction of overall mortality within two years, the prognostic performance of us-cTnI-Clarity concentrations obtained at ED presentation was superior to hs-cTnI-Architect (p<0.001) but statistically inferior compared to hs-cTnT-Elecsys (p<0.001) at all time-points within 2 years, as evaluated by time-dependent ROC curve analysis (Figure 1A). E.g. the prognostic performance to predict mortality at two years, quantified by the area under the ROC curve, was 0.75 (95% CI, 0.73–0.77) for us-cTnI-Clarity, 0.74 (95% CI, 0.72–0.76) for hs-cTnI-Architect and 0.80 (95% CI, 0.78–0.82) for hs-TnT-Elecsys.

For the prediction of future MI within two years, the prognostic performance of us-cTnI-Clarity was comparable to hs-cTnI-Architect (p=0.155) but inferior to hs-cTnT-Elecsys (p<0.001; Figure 1B).

Conclusion: Hs-cTnT is superior to us-cTnI and hs-cTnI in the prediction of all-cause mortality and future MI among patients with suspected MI.

Figure 1

Get your access to resources

Join now
  • 1ESC Professional Members – access all ESC Congress resources 
  • 2ESC Association Members (Ivory, Silver, Gold) – access your Association’s resources
  • 3Under 40 or in training - with a Combined Membership, access all resources
Join now

Our sponsors

ESC 365 is supported by Bayer, Boehringer Ingelheim and Lilly Alliance, Bristol-Myers Squibb and Pfizer Alliance, Novartis Pharma AG and Vifor Pharma in the form of educational grants. The sponsors were not involved in the development of this platform and had no influence on its content.

logo esc

Our mission: To reduce the burden of cardiovascular disease

Who we are